• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/6/24 12:31:01 PM ET
    $APM
    $BIAF
    $HSCS
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Aptorum Gr (NASDAQ:APM) stock moved upwards by 780.6% to $12.77 during Wednesday's regular session. The company's market cap stands at $66.1 million.
    • NKGen Biotech (NASDAQ:NKGN) stock rose 302.55% to $3.47. The company's market cap stands at $75.9 million.
    • Trxade Health (NASDAQ:MEDS) shares increased by 88.71% to $15.72. The company's market cap stands at $18.9 million.
    • Regencell Bioscience (NASDAQ:RGC) stock moved upwards by 80.06% to $10.39. The market value of their outstanding shares is at $135.2 million.
    • Nexalin Technology (NASDAQ:NXL) shares moved upwards by 38.94% to $0.48. The company's market cap stands at $3.5 million.
    • Vincerx Pharma (NASDAQ:VINC) shares rose 37.61% to $7.61. The company's market cap stands at $162.7 million.

    Losers

    • bioAffinity Technologies (NASDAQ:BIAF) shares decreased by 45.0% to $1.65 during Wednesday's regular session. The market value of their outstanding shares is at $15.6 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares decreased by 29.65% to $0.13. The market value of their outstanding shares is at $8.0 million.
    • Ocean Biomedical (NASDAQ:OCEA) stock fell 29.28% to $3.72. The market value of their outstanding shares is at $126.8 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 25.84% to $0.06. The market value of their outstanding shares is at $3.3 million.
    • Jaguar Health (NASDAQ:JAGX) stock declined by 25.38% to $0.09. The market value of their outstanding shares is at $4.7 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares declined by 19.05% to $1.02. The company's market cap stands at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $BIAF
    $HSCS
    $JAGX

    CompanyDatePrice TargetRatingAnalyst
    Vincerx Pharma Inc.
    $VINC
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    Vincerx Pharma Inc.
    $VINC
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    TRxADE HEALTH Inc.
    $MEDS
    12/9/2021$4.50Buy
    EF Hutton
    Vincerx Pharma Inc.
    $VINC
    11/1/2021$24.00Outperform
    SVB Leerink
    Vincerx Pharma Inc.
    $VINC
    9/13/2021$30.00Buy
    Laidlaw
    Vincerx Pharma Inc.
    $VINC
    8/25/2021$26.00Buy
    B. Riley Securities
    Vincerx Pharma Inc.
    $VINC
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    Jaguar Health Inc.
    $JAGX
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $APM
    $BIAF
    $HSCS
    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

    1/14/22 6:06:29 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

    12/23/21 6:37:41 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Trxade Health with a new price target

    EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

    12/9/21 9:10:50 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

    Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI technology has potential to improve lung cancer risk assessment and nodule management bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 146% growth compared to the first quarter of 2025, reflecting accelerating physici

    4/1/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

    Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

    3/25/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

    Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of "CyPath® Lung in Practice" webinar series focuses on need for greater certainty when diagnosing indeterminate pulmonary nodules Healthcare providers can register here for the April 8, 2026, webinar bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced it will host the first of a series of live virtual physician roundtables featuring pulmonologists who will discuss their use of CyPath® Lung in clinical practice as part of a comprehen

    3/25/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    6/2/25 12:11:05 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    5/7/25 4:05:15 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    3/13/25 4:52:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $APM
    $BIAF
    $HSCS
    $JAGX
    SEC Filings

    View All

    SEC Form 3 filed by Regencell Bioscience Holdings Limited

    3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)

    3/18/26 9:18:02 AM ET
    $RGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by Regencell Bioscience Holdings Limited

    3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)

    3/18/26 9:16:59 AM ET
    $RGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by Regencell Bioscience Holdings Limited

    3 - Regencell Bioscience Holdings Ltd (0001829667) (Issuer)

    3/18/26 9:16:06 AM ET
    $RGC
    Medicinal Chemicals and Botanical Products
    Health Care

    HeartSciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - HeartSciences Inc. (0001468492) (Filer)

    4/3/26 5:15:10 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Sunshine Biopharma Inc.

    10-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    4/3/26 11:58:23 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Jaguar Health Inc.

    NT 10-K - Jaguar Health, Inc. (0001585608) (Filer)

    4/1/26 4:19:05 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Financials

    Live finance-specific insights

    View All

    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

    Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 ("FQ1 2026") and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial progress during FQ1 2026 which saw the Company achieve an FDA Breakthrough Device Designation and successfully launched MyoVista Insights. MyoVista Insights™ Software Platform HeartScie

    9/11/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

    NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026.Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song. SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK")

    9/9/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

    Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements during fiscal year 2025, marking a pivotal shift in its strategy to enhance the clinical value of ECGs through AI and cloud-based technologies that can be deployed across diverse healthcare settin

    7/24/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $APM
    $BIAF
    $HSCS
    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care